NEW YORK, Jan 11 – Gene logic and Pfizer have entered into an agreement to jointly develop a microarray for toxicology studies using Affymetrix’s GeneChip technology, the companies announced Thursday.
Under the agreement, Gene Logic and Pfizer researchers will both design the array, and Affymetrix will build it. The array will only be available to subscribers of Gene Logic’s ToxExpress, part of its GeneExpress suite, and is designed to complement the ToxExpress’s library of toxicity markers.
The companies did not disclose the financial terms of the agreement. Gene Logic said the financial impact of the collaboration would not show up until future years.
" This custom probe array is being designed to provide a novel high-throughput platform for functional studies of known and unknown genes," Eric Eastman, Gene Logic’s Chief Technology Officer, said in a statement. " We believe this is a significant move forward that will enhance our customers' ability to more efficiently manage and evaluate the increasing volumes of genetic data and, ultimately, save costs."
This collaboration builds on two previous relationships: Pfizer has subscribed to ToxExpress since late February of last year and Gene Logic has previously provided Affymetrix with sequence information for Affymetrix’s custom microarrays.